Mineralocorticoid receptor ligands: biochemical, pharmacological, and clinical aspects.
Sutanto
W
W
Center for Bio-Pharmaceutical Sciences, Sylvius Laboratoria, University of Leiden, The Netherlands.
de Kloet
E R
ER
D000224:Addison Disease / Q000188:drug therapy; D000305:Adrenal Cortex Hormones / Q000378:metabolism; D000818:Animals; D001923:Brain Chemistry; D002192:Canrenone / Q000378:metabolism / Q000494:pharmacology; D015195:Drug Design; D006624:Hippocampus / Q000187:drug effects / Q000378:metabolism; D006801:Humans; D006929:Hyperaldosteronism / Q000188:drug therapy; D008024:Ligands; D000451:Mineralocorticoid Receptor Antagonists / Q000378:metabolism / Q000494:pharmacology* / Q000627:therapeutic use; D008901:Mineralocorticoids / Q000037:antagonists & inhibitors / Q000378:metabolism / Q000502:physiology*; D051381:Rats; D011965:Receptors, Glucocorticoid / Q000187:drug effects / Q000378:metabolism; D018161:Receptors, Mineralocorticoid; D011987:Receptors, Steroid / Q000037:antagonists & inhibitors / Q000187:drug effects* / Q000378:metabolism; D013148:Spironolactone / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology / Q000627:therapeutic use; D013329:Structure-Activity Relationship
D000305:Adrenal Cortex Hormones; D008024:Ligands; D000451:Mineralocorticoid Receptor Antagonists; D008901:Mineralocorticoids; D011965:Receptors, Glucocorticoid; D018161:Receptors, Mineralocorticoid; D011987:Receptors, Steroid; D013148:Spironolactone; D002192:Canrenone